202 related articles for article (PubMed ID: 30825048)
1. Hormone- and HER2-receptor assessment in 33,046 breast cancer patients: a nationwide comparison of positivity rates between pathology laboratories in the Netherlands.
van Dooijeweert C; Deckers IAG; Baas IO; van der Wall E; van Diest PJ
Breast Cancer Res Treat; 2019 Jun; 175(2):487-497. PubMed ID: 30825048
[TBL] [Abstract][Full Text] [Related]
2. Real-world data on discordance between estrogen, progesterone, and HER2 receptor expression on diagnostic tumor biopsy versus tumor resection material.
Berghuis AMS; van Deurzen CHM; Koffijberg H; Terstappen LWMM; Sleijfer S; IJzerman MJ
Breast Cancer Res Treat; 2019 Jun; 175(2):451-458. PubMed ID: 30756285
[TBL] [Abstract][Full Text] [Related]
3. Hormone Receptor and Human Epidermal Growth Factor Receptor 2 Detection in Invasive Breast Carcinoma: A Retrospective Study of 12,467 Patients From 19 Chinese Representative Clinical Centers.
Shui R; Liang X; Li X; Liu Y; Li H; Xu E; Zhang Z; Lian Y; Guo S; Yao M; Yang H; Xu F; Liu Y; Liu J; Guo D; Wang K; Li J; Ma Y; Wang J; Shi J; Bu H; Yang W
Clin Breast Cancer; 2020 Feb; 20(1):e65-e74. PubMed ID: 31669267
[TBL] [Abstract][Full Text] [Related]
4. Significant inter- and intra-laboratory variation in grading of invasive breast cancer: A nationwide study of 33,043 patients in the Netherlands.
van Dooijeweert C; van Diest PJ; Willems SM; Kuijpers CCHJ; van der Wall E; Overbeek LIH; Deckers IAG
Int J Cancer; 2020 Feb; 146(3):769-780. PubMed ID: 30977119
[TBL] [Abstract][Full Text] [Related]
5. Significant inter- and intra-laboratory variation in grading of ductal carcinoma in situ of the breast: a nationwide study of 4901 patients in the Netherlands.
van Dooijeweert C; van Diest PJ; Willems SM; Kuijpers CCHJ; Overbeek LIH; Deckers IAG
Breast Cancer Res Treat; 2019 Apr; 174(2):479-488. PubMed ID: 30539380
[TBL] [Abstract][Full Text] [Related]
6. Brief fixation enables same-day breast cancer diagnosis with reliable assessment of hormone receptors, E-cadherin and HER2/Neu.
Halilovic A; Bulte J; Jacobs Y; Braam H; van Cleef P; Schlooz-Vries M; Werner A; Boelens O; Nagtegaal I; de Wilt H; Bult P
J Clin Pathol; 2017 Sep; 70(9):781-786. PubMed ID: 28325747
[TBL] [Abstract][Full Text] [Related]
7. Parity, hormones and breast cancer subtypes - results from a large nested case-control study in a national screening program.
Ellingjord-Dale M; Vos L; Tretli S; Hofvind S; Dos-Santos-Silva I; Ursin G
Breast Cancer Res; 2017 Jan; 19(1):10. PubMed ID: 28114999
[TBL] [Abstract][Full Text] [Related]
8. Relapse-free survival of statistically standardized continuous RT-PCR estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2): NCIC CTG MA.14.
Chapman JA; Sgroi DC; Goss PE; Zarella E; Binns S; Zhang Y; Schnabel CA; Erlander MG; Pritchard KI; Han L; Badovinac-Crnjevic T; Shepherd LE; Pollak MN
Breast Cancer Res Treat; 2016 May; 157(1):101-8. PubMed ID: 27116182
[TBL] [Abstract][Full Text] [Related]
9. Molecular subtypes of screen-detected breast cancer.
Farshid G; Walters D
Breast Cancer Res Treat; 2018 Nov; 172(1):191-199. PubMed ID: 30046938
[TBL] [Abstract][Full Text] [Related]
10. Is breast cancer from Sub Saharan Africa truly receptor poor? Prevalence of ER/PR/HER2 in breast cancer from Kenya.
Sayed S; Moloo Z; Wasike R; Bird P; Oigara R; Govender D; Kibera J; Carrara H; Saleh M
Breast; 2014 Oct; 23(5):591-6. PubMed ID: 25012047
[TBL] [Abstract][Full Text] [Related]
11. Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials.
van Mackelenbergh MT; Denkert C; Nekljudova V; Karn T; Schem C; Marmé F; Stickeler E; Jackisch C; Hanusch C; Huober J; Fasching PA; Blohmer JU; Kümmel S; Müller V; Schneeweiss A; Untch M; von Minckwitz G; Weber KE; Loibl S
Breast Cancer Res Treat; 2018 Jan; 167(1):59-71. PubMed ID: 28875243
[TBL] [Abstract][Full Text] [Related]
12. Quality of pathology reporting is crucial for cancer care and registration: a baseline assessment for breast cancers diagnosed in Belgium in 2008.
De Schutter H; Van Damme N; Colpaert C; Galant C; Lambein K; Cornelis A; Neven P; Van Eycken E
Breast; 2015 Apr; 24(2):143-52. PubMed ID: 25572136
[TBL] [Abstract][Full Text] [Related]
13. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
[TBL] [Abstract][Full Text] [Related]
14. Frequency and reliability of oestrogen receptor, progesterone receptor and HER2 in breast carcinoma determined by immunohistochemistry in Australasia: results of the RCPA Quality Assurance Program.
Francis GD; Dimech M; Giles L; Hopkins A
J Clin Pathol; 2007 Nov; 60(11):1277-83. PubMed ID: 17259294
[TBL] [Abstract][Full Text] [Related]
15. Estrogen and progesterone receptor expression levels do not differ between lobular and ductal carcinoma in patients with hormone receptor-positive tumors.
Truin W; Roumen RMH; Siesling S; van de Vijver KK; Tjan-Heijnen VCG; Voogd AC
Breast Cancer Res Treat; 2017 Jul; 164(1):133-138. PubMed ID: 28365833
[TBL] [Abstract][Full Text] [Related]
16. Metastatic breast carcinoma in pleural fluid: Correlation of receptor and HER2 status with the primary carcinoma-a pilot study.
Francis IM; Alath P; George SS; Jaragh M; Al Jassar A; Kapila K
Diagn Cytopathol; 2016 Dec; 44(12):980-986. PubMed ID: 27666130
[TBL] [Abstract][Full Text] [Related]
17. HER2-Low Breast Cancer: Incidence, Clinicopathologic Features, and Survival Outcomes From Real-World Data of a Large Nationwide Cohort.
Baez-Navarro X; van Bockstal MR; Andrinopoulou ER; van Deurzen CHM
Mod Pathol; 2023 Apr; 36(4):100087. PubMed ID: 36788086
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of patients with inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes: A population-based study from the SEER program.
Li J; Xia Y; Wu Q; Zhu S; Chen C; Yang W; Wei W; Sun S
Oncotarget; 2017 Jul; 8(30):49370-49379. PubMed ID: 28472761
[TBL] [Abstract][Full Text] [Related]
19. Variation in breast cancer grading: the effect of creating awareness through laboratory-specific and pathologist-specific feedback reports in 16 734 patients with breast cancer.
van Dooijeweert C; van Diest PJ; Baas IO; van der Wall E; Deckers IA
J Clin Pathol; 2020 Dec; 73(12):793-799. PubMed ID: 32276993
[TBL] [Abstract][Full Text] [Related]
20. Quantitative mast cell analysis and hormone receptor study (ER, PR and HER2/neu) in invasive carcinoma of breast.
Pyla RD; Potekar RM; Patil VS; Reddy AK; Sathyashree KV
Indian J Pathol Microbiol; 2020; 63(2):200-204. PubMed ID: 32317515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
